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Abstract
Acute pancreatitis (AP) is a formidable disease, which, in severe forms, causes significant mortality. Biliary
AP, or gallstone obstruction-associated AP, accounts for 30–50% of all clinical cases of AP. In biliary AP,
pancreatic acinar cell (PAC) death (the initiating event in the disease) is believed to occur as acinar cells
make contact with bile salts when bile refluxes into the pancreatic duct. Recent advances have unveiled
an important receptor responsible for the major function of bile acids on acinar cells, namely, the cell
surface G-protein-coupled bile acid receptor-1 (Gpbar1), located in the apical pole of the PAC. High
concentrations of bile acids induce cytosolic Ca2+ overload and inhibit mitochondrial adenosine triphos-
phate (ATP) production, resulting in cell injury to both PACs and pancreatic ductal epithelial cells. Various
bile salts are employed to induce experimental AP, most commonly sodium taurocholate. Recent char-
acterization of taurolithocholic acid 3-sulphate on PACs has led researchers to focus on this bile salt
because of its potency in causing acinar cell injury at relatively low, sub-detergent concentrations, which
strongly implicates action via the receptor Gpbar1. Improved surgical techniques have enabled the
infusion of bile salts into the pancreatic duct to induce experimental biliary AP in mice, which allows the
use of these transgenic animals as powerful tools. This review summarizes recent findings using trans-
genic mice in experimental biliary AP.
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Introduction
Biliary acute pancreatitis (BAP) refers to acute pancreatitis (AP)
caused by biliary calculous diseases. It is the most common cause
of AP and is associated with significant morbidity and mortality.1
Obstruction of the common biliopancreatic duct (CBPD) by gall-
stones blocks the efflux of pancreatic zymogens, creates elevated
pressure in the pancreas and leads to bile reflux into the pancreatic
duct. A number of experimental models have been designed to
recreate this condition. The purely surgical models of BAP, such as
closed duodenal loop-induced pancreatitis and CBPD or pancre-
atic duct ligation-induced pancreatitis have been reviewed in
detail previously2,3 and thus are beyond the scope of the current
review. Cannulation of the pancreatic duct has enabled research-
ers to apply the bile components into the pancreas of experimen-
tal animals in a more controlled way. One of the most significant
recent advances involves the adaptation of this technique to a
mouse model, which opens the door to transgenic studies of BAP.
Another significant development refers to observations of a
variety of bile salts that induce pathological responses in single
acinar cells in vitro, elucidating some molecular mechanisms of
the detrimental action of pancreatic bile. In addition, some*These authors contributed equally to this work.
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important knowledge on the role of pancreatic duct epithelial cells
(PDECs) in the pathogenesis of BAP has recently emerged. Finally,
this review summarizes recent advances in basic research and
highlights further research prospects in the pursuit of effective
clinical interventions in BAP.
Bile acids and their targets
Bile acids, in addition to their known functions in dietary fat
absorption and cholesterol metabolism through nuclear recep-
tors,4,5 also induce cellular signalling through the recently
described cell surface G-protein-coupled bile acid receptor-1
(Gpbar1), found in brown adipose tissue, intestine and gallblad-
der in mammals.5–7 When Gpbar1 receptor is activated by bile
acids, it can modulate energy homeostasis, lipid homeostasis and
glucose homeostasis,8,9 and stimulate gallbladder filling.6
In hepatocytes, choleretic and cholestatic bile acids activate and
inhibit store-operated Ca2+ channels, respectively, throughmecha-
nisms which involve reversible redistribution of stromal interac-
tion molecule 1.10,11 In pancreatic acinar cells (PACs), bile acid
transporters, namely, the Na+-dependent Na+ taurocholate
co-transporting polypeptide (NTCP), located at the apex of
the cell, and HCO3--dependent organic anion transporting
polypeptide-1 (OATP1), located on the basolateral portion of the
cell membrane, have recently been identified.12 The bile receptor
Gpbar1 is also located in the apical region of the cell and is
positioned to respond to bile in the lumen of the duct.13 The bile
acid transporters and receptor constitute the molecular machin-
ery responsible for the pathological action of refluxed or circu-
lated bile acids on PACs.14,15 Detailed bile acid uptake and targets
in PACs have been reviewed recently by Lerch and Aghdassi.14
Effects of bile acids on acinar cells
In 2002, Voronina et al.16 demonstrated the effect of taurolitho-
cholic acid 3-sulphate (TLC-S) on isolated murine PACs. TLC-S
induced Ca2+ oscillations at concentrations as low as 25 mm and
triggered responses in almost all cells at 200 mm. At higher con-
centrations of 300–500 mm, TLC-S caused longlasting Ca2+ rises
comprised of initial release from intracellular Ca2+ stores and fol-
lowed by the influx of extracellular Ca2+. The study found that
other bile salts, taurodeoxycholate (TDC) and taurocholate (TC),
also triggered local and global Ca2+ oscillations, although at much
higher concentrations (1 mm and 5 mm, respectively).16
These data highlight the role of TLC-S not only as the most
potent Ca2+ releaser among bile acids tested on PACs so far, but
also as the most effective bile acid in inducing Ca2+-independent
current, even at 10 mm. This concentration is close to the concen-
trations of sulphated lithocholic acid conjugates detected in
serum in different pathological conditions.17 Indeed, in patients
with severe extrahepatic duct obstruction, concentrations of bile
acids of ~200 mm have been detected in peripheral circulation.18
Subsequently, Voronina et al. and other groups revealed that
bile acids mediated intracellular Ca2+ release from both endoplas-
mic reticulum and acidic intracellular Ca2+ stores through the
activation of inositol trisphosphate receptors (IP3R) and ryanod-
ine receptors,19–21 the inhibition of sarco/endoplasmic reticulum
Ca2+-ATPase pumps and the activation of store-operated Ca2+
entry,12 and also reduced mitochondrial membrane potential22
and depleted both cytosolic and mitochondrial adenosine triph-
osphate (ATP),23 leading to cellular injury.
Effects of bile acids on pancreatic duct cells
Although PACs have been extensively characterized, it is surpris-
ing that few studies have addressed issues of pancreatic duct cells
under stressful conditions such as bile acid stimulation. Encour-
agingly, the work carried out byVenglovecz et al.24 investigated the
effects of bile acids on cells of the pancreatic duct. This study has
shed some light on the role of pathological agents in the function
of the ductal system.
Pancreatic duct epithelial cells and PACs have mutual commu-
nication and share similar responses to bile acids.25 Pancreatic
duct epithelial cells play a fundamental role in secreting fluid rich
in HCO3- to wash out harmful digestive enzymes secreted by PACs
and in neutralizing acid chyme in the duodenum. Therefore,
PDECs represent the first line of defence against bile acid reflux.25
Venglovecz et al. found that a low concentration (100 mm) of
unconjugated bile acid chenodeoxycholate (CDC) stimulated
HCO3- secretion via phospholipase C- and IP3-mediated Ca2+ sig-
nalling in PDECs.24 By contrast, high-concentration (1 mm) CDC
inhibited HCO3- secretion, suppressed the glycolytic metabolism
of PDECs and depleted mitochondrial ATP, causing mitochon-
drial damage.26 However, conjugated bile salt glycochenodeoxy-
cholate (GCDC)-elevated intracellular Ca2+ signals failed to
stimulate or inhibit HCO3- secretion at various concentrations
and caused no morphological change in mitochondria.26 Further
work in guinea pigs identified Ca2+-activated large conductance K+
channels expressed at the apical membrane of PDECs, which play
a crucial role in regulating bile acid-stimulated or -inhibited
HCO3- secretion.27
Induction of AP by bile salts
The first experimental BAP model was established in 1856 by
Bernard,28 who developed a method of retrograde injection of bile
and olive oil into a canine pancreas through the ampulla of Vater.
Since then, various bile salts such as sodium CDC (Na-CDC),
sodium TC (Na-TC), sodium glycodeoxycholic acid (Na-GDC),
TDC (Na-TDC) and TLC-S have been reported to induce AP in
different species.
Model of pancreatitis induced by Na-CDC
Very few studies have employed the non-conjugated bile salt,
Na-CDC, to study the pathogenesis of AP or the effects of treat-
ment regimens. This procedure sometimes requires simultaneous
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ligation of the pancreatic duct and was found to cause necrotizing
pancreatitis and associated lung injury in rats (5%, 2 ml/kg)29,30
and rabbits.31,32
Model of pancreatitis induced by Na-GDC
An early study demonstrated that ductal infusion of 100 ml of
the glycine-conjugated bile salt, Na-GDC, at concentrations of
8.5 mm, 17 mm and 34 mm, caused progressive, severe but non-
lethal AP in rats.33 Na-GDC infusions of 17 mm and 34 mm
caused oedematous and necrotizing pancreatitis, respectively.34–36
When 200 ng enterokinase was administrated with 34 mm
Na-GDC infusate, necrotic pancreatitis with systemic disturbance
and rapid lethality was produced.33
In 1992, Schmidt et al.37 established a new model in rats using
the combined actions of very low concentrations of ductal infu-
sion of Na-GDC (5 mm or 10 mm) and i.v. caerulein injection
(5 mg/kg/h for 6 h). This model features a moderate onset of
homogeneous moderate pancreatic injury that lasts 24 h and
provides the potential for modulating severity, as well as clinical
relevance. Therefore, this model is particularly suitable for use in
the evaluation of new therapeutic modalities and has been used
frequently in subsequent studies.38–41
Model of pancreatitis induced by Na-TDC
The Na-TDC model was initially used in the 1980s,42,43 both with
and without ductal infusion of various concentrations of
trypsin. Thereafter, the model was employed frequently to
explore the pathogenesis of AP with a commonly adopted
regimen of 200 ml of 5% Na-TDC in the rat. Common findings
included the perturbation of energy metabolism in the intestinal
wall,44 impaired intestinal permeability,45 bacterial translo-
cation,46,47 formation of platelet-activating factor,48 pulmonary
endothelial barrier dysfunction,49 microvascular endothelial
barrier dysfunction,50 activation of mast cells,51–53 induction of
nitric oxide synthase,54 over-induced polyamine catabolism,55–57
increased high-mobility group box,58 increased catalytic activity
of phospholipase A,59 upgraded cytokine levels60,61 and increased
myeloperoxidase (MPO) activity.61
Models of pancreatitis induced by Na-TC and TLC-S
Among these bile salts, the taurine-conjugated bile salt Na-TC is
the most widely used and best characterized to date in inducing
AP. The Na-TC ductal infusion model has been shown to induce
pancreatic oedema, haemorrhage and necrosis in large animals,
such as rabbits,62 swans,63 dogs64 and pigs.65,66 However, the pan-
creatic injury in these large animals is not sufficient to produce
multiple organ dysfunction syndromes (MODS). Instead, the rat
model of Na-TC infusion serves as a well-defined tool to research
MODS in severe AP, as evidenced by lung,67,68 liver,69 gastric,70
intestinal,71,72 kidney72,73 and brain72,74 impairments, which mirror
events in the human condition. Once infusion pressure and speed
have been fixed by a pump, the severity of pancreatitis is deter-
mined by the concentration and volume of Na-TC infused. The
regimen of Na-TC infusion was later standardized by Aho
et al.75–77 in a series of studies in rats. The volume of 0.2 ml/kg at
concentrations of 3.0%, 4.5% or 5.0% induced acute haemor-
rhage pancreatitis with 72-h mortality rates of 24%, 71% and
100%, respectively. Like the caerulein/lipopolysaccharide (LPS)
model, this model is suitable for the study of bacterial transloca-
tion when combined with LPS,78 which has a dose-dependent
effect on lethality in rats,79 and results in more severeMODSwhen
trypsin is superimposed on the Na-TC/LPS model.80 In a recent
study, Zhou et al.81 reported amodel of infected severe AP induced
by ductal infusion of Na-TC and Escherichia coli in rats.
Experimental pancreatitis induced by Na-TC in the rat may
have represented the reference standard of BAP for many years.
However, the technique has recently been extended to the mouse
model,82 thereby enabling the increased utility of genetic
approaches.83 TLC-S, which has now been extensively character-
ized, is favoured by researchers over Na-TC in the induction of AP.
Table 1 summarizes the characteristics of pancreatitis induced by
Na-TC in different species.
Recent advances in experimental BAP in mice
Recently, Laukkarinen et al.82 established a non-lethal BAP
model in mice using a retrograde ductal infusion of 50 ml 2%
Na-TC and published a detailed methodology.84 This protocol
produced necrotizing pancreatitis in the head of the pancreas,
but did not elicit associated lung injury. These authors’ parallel
in vitro findings confirmed that Na-TC induced pathological
Ca2+ signals and Ca2+-dependent trypsinogen activation and cell
death in isolated PACs. This model in mice has been further
validated.85,86 Ductal infusions at 2 ml/kg of 4% and 5% Na-TC
resulted in necrotizing pancreatitis, lung injury and increased
cytokines, causing mortality rates of 10% and 60% at 24 h,
respectively.85 These new developments allow for coherent, coor-
dinated studies of pancreatic pathological stimuli on many
layers of scale from isolated mitochondria87 to whole animals,88
especially genetically manipulated mice.
Gpbar1
The presence of Gpbar1 on the apical pole of PACs was first
identified by Perides et al.13 using C57BL/6 mice deleted for
Gpbar1. These authors infused 50 ml of 3 mm TLC-S or Na-TC
into the pancreatic duct and found that, whereas TLC-S injection
caused pancreatitis, Na-TC failed to do so. Gpbar1 knockout mice
were completely protected against pancreatitis induced by TLC-S.
In their parallel in vitro study, they found that 500 mm TLC-S
elicited pathological Ca2+ signals, intrapancreatic trypsinogen
activation and cell death in isolated PACs.13 Again, these effects
were mostly absent in PACs from Gpbar1-/- mice. Interestingly,
500 mm TLC-S was still able to induce amylase secretion in isolated
PACs from Gpbar1-/- mice, an event that was Ca2+-dependent.
When the concentration of TLC-S was increased to 1 mm, the
induced amylase secretion seemed to be neither Gpbar1- nor
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Ca2+-dependent. These findings suggest that: (i) the mechanism
by which TLC-S acts on PACs is independent of bile acid
co-transporters and exchangers, and occurs specifically through
luminal surface Gpbar1; (ii) as amylase secretion seems to be
independent of Gpbar1 and, at higher concentrations, even
independent of Ca2+, non-receptor-mediated mechanisms may
also account for complicated effects of bile acids on PACs, and (iii)
unlike caerulein, TLC-S does not block pancreatic secretion,
which suggests that the early damage to the pancreas during
AP, at least in the case of TLC-S, can occur independently of
the inhibition of zymogen secretion and intracellular trypsin
activation.
Cathepsin L
Cathepsins are proteases that break down other proteins. They are
found in all animals in many types of cell and are classified
according to structure and catalytic type into serine, aspartic and
cysteine families, the last of which includes cathepsin B and cathe-
psin L.89 Cathepsin B inhibitors or gene knockout have been found
to block trypsinogen activation in vitro90 and to protect against
AP in vivo.91–93 Cathepsin L demonstrates enzymatic properties
similar to those of cathepsin B and is widely expressed and exhib-
its much stronger endoproteolytic activity than cathepsin B.94
The role of cathepsin L in AP was recently investigated by
Wartmann et al.95 using Ctsl-/- mice96 in models of pancreatitis
induced by Na-TC (2%, 50 ml) and caerulein, respectively. Simi-
larly to cathepsin B,97 cathepsin L was expressed in human and
mouse exocrine pancreas. In pancreatitis, it was found to be colo-
calized with trypsinogen and to be secreted into pancreatic juice.
By contrast with Ctsb-/- mice, which showed a decrease in trypsin
activity, Ctsl-/- mice demonstrated increased intrapancreatic
trypsin activity upon pancreatitis.95 Interestingly, Ctsl-/- mice
showed promoted apoptosis and reduced severity of pancreatitis
compared with their littermates. These findings suggest that intra-
pancreatic trypsin activity may not reflect the severity of AP, and
the crosstalk among trypsinogen activation, cathepsin B and
cathepsin L needs further investigation.
Toll-like receptor 9 and NOD-like receptor
3 inflammasome
Zhang et al.98 recently demonstrated that cellular injury can
release into the circulation endogenous damage-associated
molecular patterns (DAMPs) that activate polymorphonuclear
neutrophils through formyl peptide receptor-1 and Toll-like
receptor-9 (TLR9), respectively. TLR9 is expressed on the cell
surface and endocytic compartment and plays an important role
in detecting self molecules and DNA.99 NOD-like receptor-3
(NLR3) is expressed in cytosol and is required by uric acid and
ATP for inflammasome activation via plasma membrane purier-
gic receptor P2X7, which is activated by DAMPs.100,101
Hoque et al.102 studied the roles of TLR9, NLRP3 inflamma-
some (NLRP3-ASC) and DAMPs in AP using models of AP
induced by TCL-S (3 mm, 50 ml) and caerulein, respectively. They
found that, in the early stages of AP, circulating genomic DNA was
markedly increased, but serum mitochondria appeared to be
unaltered. This suggests that mitochondrial DAMPs may be
largely restricted to the injury site.103 Deletion of TLR9 or appli-
cation of its antagonist IRS954, as well as deletion of inflamma-
some components NLRP,ASC and P2X7 receptor or application of
P2X7 receptor antagonist A-439079, were all shown to reduce the
severity of AP induced by caerulein.102 Moreover, pancreatic pro-
interleukin-1b (pro-IL-1b) mRNA was reduced in TLR9-/- or
Table 1 Characteristics of models of pancreatitis induced by Na-TC in different species
Dose Species Effect Reference(s)
10%, 1.0 ml/kg Dog Significantly increased serum and ascites amylase, lipase levels; pancreatic parenchymal
oedema, inflammatory cell infiltration and necrosis; other organ injury: N/A
64
5%, 1.0 ml/kg Rabbit Pancreatic oedema, inflammatory cell infiltration, necrosis, haemorrhage and fat necrosis;
other organ injury: N/A
62
20%, 1.0 ml/kg Pig Significantly increased serum lipase level, WBC counts and neutrophils; significantly
decreased mean blood pressure, serum lymphocytes and platelets; pancreatic oedema,
haemorrhage, necrosis and accumulation of neutrophils, lymphocytes and macrophages;
other organ injury: N/A
66
5%, 0.5 ml/kg plus
5% trypsin
Pig Significantly increased serum amylase and WBC counts; focal liquefactive necrosis in most
of the pancreas, with neutrophil infiltration; other organ injury: N/A
63
3–5%, 1.0 mg/kg Rat Significantly increased serum amylase, lipase and proinflammatory cytokine levels;
pancreatic oedema, vacuolization, inflammation, haemorrhage, acinar cell and fat
necrosis; lung, liver, gastric, kidney and brain injuries
67–72,74,123–125
2%, 50 ml Mouse Increased serum amylase and IL-6; transient increase of intrapancreatic trypsin activity;
pancreatic oedema, leukocyte infiltration and necrosis; no mortality
82
4%, 5%, 2.0 ml/kg Mouse Increased serum amylase, lipase and IL-6; decreased serum IL-12; pancreatic oedema,
leukocyte infiltration, necrosis, haemorrhage and fat necrosis; increased pulmonary BAL
fluid albumin and MPO activity; 10% and 60% mortality rates at 24 h for 4% and 5%
Na-TC, respectively
85
Na-TC, sodium taurocholate; WBC, white blood cell; IL, interleukin; BAL, bronchoalveolar lavage; MPO, myeloperoxidase; N/A, not applicable.
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TLR9 antagonist-treated mice. In pancreatitis induced by TLC-S,
pretreatment with TLR9 antagonist IRS954 significantly reduced
serum amylase, pancreatic oedema, inflammation, necrosis and
lung histology.102 This study highlighted new therapeutic poten-
tials of DAMPs-receptor pathway antagonism, such as TLR9 and
P2X7 receptor antagonists.
Tumour necrosis factor-a and Ly-6Chi monocytes
Recently, genetically altered mouse strains have been employed to
show either the complete deletion of tumour necrosis factor-a
(TNF-a) or the expression of human diphtheria toxin receptor
(DTR) coupled to the CD11b promoter (CD11b-DTR).104 In
CD11b-DTR mice, the severity of pancreatitis was associated with
pancreatic Ly-6Chi monocytes/macrophages,105 which are released
from bone marrow to injured tissue in response to distant organ
injuries.106 Prior administration of diphtheria toxin (DT) abol-
ished Ly-6Chi monocytes and prevented pancreatic oedema and
necrosis in pancreatitis induced by either caerulein or Na-TC
(37 mm, 50 ml). This protective effect by DT was reversed by adop-
tive transfer of purified Ly-6Chi monocytes harvested from
CD11b-DTR mice or TNF-a+/+ donors but not from TNF-a-/-
donor mice.105 These findings indicate that monocytes and mac-
rophages regulate pancreatic oedema and necrosis through the
TNF-a pathway and therefore that targeting either Ly-6Chi mono-
cytes or TNF-a may represent a promising strategy in the treat-
ment of AP. Indeed, TNF-a antagonism has been evaluated as a
pharmacological strategy for treating pancreatitis in response to
promising results in numerous studies of various experimental AP
models.107,108 However, other reports have demonstrated that
TNF-a blockage was ineffective in the prevention of post-
endoscopic retrograde cholangiopancreatography pancreatitis in
canines109 and even augmented the severity of caerulein-induced
pancreatitis in rats.110 Moreover, neutralization of TNF-a has
failed in sepsis clinical trials.111–113 These findings indicate that the
extrapolation of laboratory results into clinical trials is complex.
Rho-kinase, lymphocyte function antigen-1
and CD40 ligand
Awla et al.114,115 and Abdulla et al.116 investigated the roles of Rho-
kinase, lymphocyte function antigen-1 (LFA-1) and CD40 ligand
(CD40L) in experimental AP induced by Na-TC (5%, 10 ml)
and/or caerulein. Rho-kinase inhibitor Y-27632 (5 mg/kg), given
prior to the induction of pancreatitis, was found to dramatically
reduce the severity of AP and associated lung injury.114 Moreover,
pancreatitis-induced trypsinogen activation peptide levels were
reduced in vivo and in vitro (caerulein) by Y-27632 treatment.
However, the administration of Y-27632 after induction of pan-
creatitis had no significant effect on pancreatic or systemic inju-
ries. These authors therefore postulated that Rho-kinase inhibitor
may regulate trypsinogen activation in pancreatitis.114 In another
study, they showed that both LFA gene deletion and anti-LFA-1
antibody were protective against AP in genetically targeted LFA-1
mice.115 The inhibition of LFA-1 function not only greatly reduced
Na-TC-induced leukocyte adhesion, neutrophil accumulation in
the pancreas and acinar cell necrosis, but also attenuated pulmo-
nary neutrophil infiltration. However, trypsinogen activation
induced by Na-TC was not affected.115 The authors concluded that
LFA-1 may act on a downstream pathway of trypsinogen activa-
tion and that blocking LFA-1may provide therapeutic potential.115
CD40L is a transmembrane glycoprotein that belongs to the TNF
family of cell surface interaction molecules.117 Induced to express
mainly on a CD4+ T cell subset, it has been found to activate
platelets and to exert proinflammatory117–120 and procoagulant
effects.121,122 Abdulla et al. examined responses in CD40L-/-mice to
AP induced by either Na-TC or caerulein, but observed no ben-
eficial effects in CD40L-/- mice compared with their littermates.116
Conclusions
The extensive research conducted over the last decade has
advanced our understanding of the deleterious effects of bile
acids/salts on PACs and PDECs in the pathogenesis of BAP. As
BAP models mirror the aetiology of gallstone-induced pancreati-
tis in the clinical setting, the application of these models in mice
would facilitate studies on genetic aspects of this disease, as well as
allowing the scrutiny of candidate therapeutic drugs. Recent
advances in basic research using this BAP model have revealed the
importance of Gpbar1 and cathepsin L, and have provided poten-
tial therapeutic targets such as the DAMPs-receptor pathway,
TNF-a and Ly-6Chi monocytes. Further investigation might even-
tually lead to the discovery of effective treatments for AP.
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